Stevanato Group Presents Vertiva™, a Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies and for Large Delivery Volumes (up to 10mL)
2023年6月12日 - 9:00PM
ビジネスワイヤ(英語)
The Company offers the platform as a readily customizable
pre-filled and pre-loaded on-body solution for drug delivery.
Device development is making significant progress, with samples
expected to be available in 2023
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider
of drug containment and delivery solutions to the pharmaceutical,
biotechnology and life sciences industries, unveiled today
Vertiva™, the latest release of its patented On-Body Delivery
System (OBDS), intended to be able to switch between basal and
bolus injections and to be suitable for a wide range of
subcutaneous therapies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230608005173/en/
Vertiva™ On-Body Delivery System (Photo:
Business Wire)
Vertiva™’s unique design consists of a single-use pod with a
pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use
controller, offering potential sustainability and affordability
benefits. These two parts communicate through a patented
magnetically coupled drive mechanism. The device can adapt to
different delivery profiles and can enable the administration of
small-molecule drugs and biologics. Vertiva™ ‘s design is under
development also to cover a broad range of volumes up to 10mL.
In the Vertiva™ device the cartridge is preloaded and sealed
into the pod during factory assembly allowing the patient to
benefit from simplified treatment initiation. Administrations can
be conducted more comfortably at home, and the connectivity options
of Vertiva™ can be ready for digital health applications. Upon
treatment, the pod and controller can be more easily separated, and
the controller can be reused, thereby reducing the environmental
impact of electronic components.
Totally programmable to deliver micro-precision basal doses and
full-content bolus injections, Vertiva™ is intended to be suitable
for a wide range of therapies, such as cardiovascular and metabolic
disorders, oncology, immunology, and pain diseases. Vertiva™
platform can also accommodate different customizations, including
primary packaging format for larger injection volumes, delivery
duration, and user interface.
The Vertiva™ brand name takes its cue from the word
‘versatility’ and suggests that the delivery profile is flexible,
as it is programmable for basal and bolus delivery. The name also
evokes ease of use for patients.
Stevanato Group will leverage the recently announced
collaboration with Thermo Fisher Scientific to bring Vertiva™ to
market. The platform will be offered as an integrated device and
fill-and-finish solution to streamline the management of the
pharmaceutical supply chain. The unparalleled combination of
capabilities from two established industry providers can support
pharma companies from drug development through to the final
packaged product. Along with the proprietary device platform,
Stevanato Group will offer its pre-sterilized EZ-fill® cartridges
as drug containment solutions and assembly equipment, while Thermo
Fisher will provide fill-and-finish and final assembly
services.
“The Vertiva™ on-body delivery system
supports pharma companies in increasing the accessibility of
in-home care and administered treatment options, which can
ultimately lead to an improved patient experience,” said Steven
Kaufman, VP for Drug Delivery Systems at Stevanato Group. “We are
excited to be offering this device to the market, as it contributes
to further strengthening our integrated capabilities in the drug
delivery space. By utilizing a re-usable controller, we work
towards greater sustainability and see cost benefits to our
customers that use Vertiva™.”
Visit Stevanato Group’s website to learn more about Vertiva™ and
request information on samples.
Forward-Looking Statements
This press release may include forward-looking statements. The
words "making", “expected”, "to be", “intended”, “can”,
“potential”, “will”, and similar expressions (or their negative)
identify certain of these forward-looking statements. These
forward-looking statements are statements regarding the Company's
intentions, beliefs or current expectations concerning, among other
things, the investments the Company expects to receive, the
expansion of manufacturing capacity, the Company’s plans regarding
its presence in the U.S. market, business strategies, the Company’s
capacity to meet future market demands and support preparedness for
future public health emergencies, and results of operations. The
forward-looking statements in this press release are based on
numerous assumptions regarding the Company’s present and future
business strategies and the environment in which the Company will
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward looking
statements. Many of these risks and uncertainties relate to factors
that are beyond the Company's ability to control or estimate
precisely, such as future market conditions, currency fluctuations,
the behavior of other market participants, the actions of
regulators and other factors such as the Company's ability to
continue to obtain financing to meet its liquidity needs, changes
in the political, social and regulatory framework in which the
Company operates or in economic or technological trends or
conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, the company
assumes no obligation to update any such forward-looking
statements.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: stevanatogroup.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230608005173/en/
Media Stevanato Group Stevanato Group:
media@stevanatogroup.com Cassie Gonzalez:
stevanatoUS@teamlewis.com
Investor Relations Stevanato Group Lisa Miles:
lisa.miles@stevanatogroup.com
Stevanato (NYSE:STVN)
過去 株価チャート
から 5 2024 まで 6 2024
Stevanato (NYSE:STVN)
過去 株価チャート
から 6 2023 まで 6 2024